Icon Plc (NASDAQ:ICLR) has earned an average rating of “Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $149.00.
Several analysts have weighed in on the stock. BidaskClub upgraded shares of Icon from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. UBS Group assumed coverage on shares of Icon in a research note on Tuesday, October 9th. They set a “sell” rating and a $145.00 target price for the company. KeyCorp boosted their target price on shares of Icon from $152.00 to $157.00 and gave the company an “overweight” rating in a research note on Tuesday, September 11th. Robert W. Baird upped their price target on shares of Icon from $154.00 to $157.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. Finally, Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a research report on Thursday, August 9th.
ICLR stock opened at $141.73 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17. Icon has a 1-year low of $101.22 and a 1-year high of $155.33. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 26.29, a price-to-earnings-growth ratio of 1.95 and a beta of 0.50.
Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, October 24th. The medical research company reported $1.54 earnings per share for the quarter, meeting the consensus estimate of $1.54. Icon had a net margin of 12.88% and a return on equity of 26.08%. The firm had revenue of $655.02 million during the quarter, compared to analyst estimates of $654.66 million. Equities research analysts predict that Icon will post 6.08 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale grew its position in shares of Icon by 119.7% during the third quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock worth $113,000 after acquiring an additional 419 shares during the last quarter. Fort L.P. bought a new position in shares of Icon during the second quarter worth about $121,000. Capital Advisors Ltd. LLC bought a new position in shares of Icon during the third quarter worth about $121,000. Csenge Advisory Group bought a new position in shares of Icon during the third quarter worth about $150,000. Finally, Prudential Financial Inc. bought a new position in shares of Icon during the third quarter worth about $200,000. Institutional investors and hedge funds own 85.09% of the company’s stock.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: How to Invest in an Index Fund
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.